雷莫芦单抗联合索拉非尼作为肝癌二线治疗的疗效。
Efficacy of Ramucirumab Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.
机构信息
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
出版信息
Anticancer Res. 2021 Apr;41(4):2187-2192. doi: 10.21873/anticanres.14993.
BACKGROUND/AIM: The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml.
PATIENTS AND METHODS
In our prospectively registered, real-world cohort, 13 and 11 patients treated with ramucirumab or sorafenib, respectively, were analyzed. Progression-free survival (PFS) was primarily compared between the ramucirumab and sorafenib groups.
RESULTS
The PFS was significantly longer in the ramucirumab group than in the sorafenib group (median, 2.7 vs. 0.9 months, respectively; p=0.005). There were no significant differences in the objective response rates or the disease control rates between the ramucirumab and sorafenib groups (9.1% and 54.5% vs. 0.0% and 22.2%, respectively).
CONCLUSION
Subsequent systemic therapy with ramucirumab showed a better ability to control tumor progression than sorafenib in HCC patients with serum AFP levels ≥400 ng/ml.
背景/目的：本研究旨在评估雷莫芦单抗对比索拉非尼作为血清甲胎蛋白（AFP）水平≥400ng/ml 的肝细胞癌（HCC）患者后续系统治疗的疗效。
患者和方法
在我们前瞻性注册的真实世界队列中，分别分析了接受雷莫芦单抗或索拉非尼治疗的 13 例和 11 例患者。主要比较了雷莫芦单抗组和索拉非尼组的无进展生存期（PFS）。
结果
雷莫芦单抗组的 PFS 明显长于索拉非尼组（中位数分别为 2.7 个月和 0.9 个月，p=0.005）。雷莫芦单抗组和索拉非尼组的客观缓解率和疾病控制率无显著差异（9.1%和 54.5%比 0.0%和 22.2%）。
结论
对于血清 AFP 水平≥400ng/ml 的 HCC 患者，雷莫芦单抗后续系统治疗控制肿瘤进展的能力优于索拉非尼。
Zotero 插件